Latest News and Press Releases

Konsolideret delårsrapport 1. januar – 30. september 2024 Selskabsmeddelelse nr. 30 – 15. november 2024   Hovedpunkter fra delårsrapporten for perioden 1. januar - 30. september 2024 ...

Consolidated Interim report 1 January – 30 September 2024 Company announcement no. 30 – November 15, 2024 Key points from the Q1-Q3-2024 report (period 1 January - 30 September 2024) On 15...

Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har opnået patentbeskyttelse i Japan på behandling af colorectal cancer med RNX-051. 23. oktober 2024 Selskabsmeddelelse nr. 29 ...

     Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051. October 23, 2024Company Announcement...

     Storaktionærmeddelelse - Pharma Equity Group A/S  14. oktober 2024Selskabsmeddelelse nr. 28 Pharma Equity Group A/S har i henhold til kapitalmarkedslovens § 38 modtaget storaktionærmeddelelse om,...

     Major shareholder announcement - Pharma Equity Group A/S 14 October 2024Announcement No. 28  Pharma Equity Group A/S has, in accordance with section 38 of the Capital Markets Act, received major...

14. oktober 2024Meddelelse nr. 27 Ledende medarbejderes transaktioner Pharma Equity Group A/S har i dag modtaget meddelelse i henhold til artikel 19 i forordning (EU) nr. 596/2014 om nedenstående...

October 14,2024Announcement no. 27 Managers’ transactions  Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions...

     Pharma Equity Group offentliggør succesfuld gennemførsel af rettet emission 11. oktober 2024Meddelelse nr. 26  Med henvisning til selskabsmeddelelse nr. 25 fra 4. oktober 2024 kan Pharma Equity...

     Pharma Equity Group announces successful completion of directed issue of new shares 11 October 2024Company Announcement no 26  With reference to company announcement no. 25 from 4. October 2024,...